Design, synthesis and molecular modeling of novel aryl carboximidamides and 3-aryl-1,2,4-oxadiazoles derived from indomethacin as potent anti-inflammatory iNOS/PGE2 inhibitors
作者:Mamdouh F.A. Mohamed、Adel A. Marzouk、Ayman Nafady、Dalia A. El-Gamal、Rasha M. Allam、Gamal El-Din A. Abuo-Rahma、Hussein I. El Subbagh、Amr H. Moustafa
DOI:10.1016/j.bioorg.2020.104439
日期:2020.12
counterparts derived from indomethacin 1 were synthesized. Most of the target compounds displayed lower LPS-induced NO production IC50 in RAW 264.7 cells and potent in vitro iNOS and PGE2 inhibitory activity than indomethacin. Moreover, in carrageenan-induced rat paw oedema method, most of them exhibited higher in vivo anti-inflammatory activity than the reference drug indomethacin. Notably, 4 hrs after carrageenan
NSAIDs / iNOS抑制剂杂种的开发是通过抑制PGE 2和NO过量产生来治疗炎性疾病的新策略。合成了一系列新的芳族羧酰亚胺化合物4a-g和它们的吲哚美辛1衍生的环化的3-芳基-1,2,4-恶二唑5a-g对应物。与吲哚美辛相比,大多数目标化合物在RAW 264.7细胞中显示出更低的LPS诱导的NO产生IC 50,并且在体外iNOS和PGE2的抑制作用强。此外,在角叉菜胶诱导的大鼠爪水肿方法中,大多数在体内表现出较高的抗炎活性比消炎痛参考药多。值得注意的是,在角叉菜胶注射后4小时,在本研究中,化合物4a被证明是最有效的抗炎药,其活性分别比参比药物消炎痛(1)和塞来昔布高2倍和8倍。化合物4a被证明是LPS诱导的NO产生,iNOS活性和PGE2的抑制剂,IC 50为10.70μM,2.31μM和29 nM;分别。与1相比,化合物4a和5b具有最低的致溃疡性负债(分别为35%和38%)。组织